<DOC>
	<DOCNO>NCT02745717</DOCNO>
	<brief_summary>Aim : To evaluate additional cord blood transfusion could accelerate hematopoietic reconstitution severe aplastic anemia ( SAA ) patient receive immunosuppressive therapy ( IST ) . Study design : open-labed , prospective , multicenter , randomize control study Number subject : 60 group Treatment : IST group : ATG ( Thymoglobuline® , Genzyme ) 3.5mg/kg/d×5d plus oral cyclosporine A ( CSA ) Cord blood transfusion group : In addition dose course ATG CSA , one unit cord blood 2 HLA-A , B DRB1 mismatch transfuse 24h last dose ATG administration .</brief_summary>
	<brief_title>The Efficacy Immunosuppressive Therapy Combined With Cord Blood Transfusion Treatment Severe Aplastic Anemia</brief_title>
	<detailed_description>Eligible patient 60 year old confirm SAA , without HLA match sibling previous ATG treatment history . Patients exclude present fatal disease , include respiratory failure , heart failure , liver kidney function failure et al severely allergic biologic product . To evaluate additional cord blood transfusion could accelerate hematopoietic reconstitution severe aplastic anemia ( SAA ) patient receive IST therapy , 120 eligible patient randomize two group , IST group cord blood transfusion group . Patients IST group receive standard IST include ATG ( Thymoglobuline® , Genzyme ) 3.5mg/kg/d×5d plus oral cyclosporine A（CSA ) start 5mg/kg/d adjust maintain trough serum concentration 200-300ng/ml . While patient cord blood transfusion group receive dose course ATG CSA control group one unit cord blood 2 HLA-A , B DRB1 mismatch transfuse 24h last dose ATG administration . The neutrophil recovery day define first day 3 consecutive day absolute neutrophil count ( ANC ) &gt; 0.5×109/L , without G-CSF adminstration . Platelet recovery day deﬁned occur ﬁrst 7 consecutive day blood platelet count ( BPC ) &gt; 20×109/L , without transfusion support . Response ( CR , PR NR ) evaluate 3 , 4 , 6,9 , 12 , 18 24months treatment . The primary end point neutrophil recovery day second end point response rate ( CR+PR ) , treatment related mortality , disease free survival overall survival .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>1．Diagnosis AA confirm bone marrow aspirate biopsy , myelodysplastic syndrome paroxysmal nocturnal hemoglobinuria exclude . To confirm severe AA , patient must fulfill least two criterion : ) ANC &lt; 0.5×109/L , ii ) PLT &lt; 20×109/L iii ) Ret &lt; 20×109/L , addition , ANC &lt; 0.5×109/L must include . 2 . Under 60 year old , male female . 3 . No HLA match sibling . 4 . No previous ATG treatment history . 5 . Performance status score 2 ( ECOG criterion ) . 6．Adequate organ function define follow criterion : ALT , AST total serum bilirubin &lt; 2×ULN ( upper limit normal ) Serum creatinine BUN &lt; 1.25×ULN . 7 . Adequate cardiac function without acute myocardial infarction , arrhythmia atrioventricular block , heart failure , active rheumatic heart disease cardiac dilatation . 8．Signed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment . 9 . Willingness ability comly schedule visit , treatment plan , laboratory test , study procedure . 1 . Presence condition inappropriate HSCT . 2 . Presence fatal disease , include respiratory failure , heart failure , liver kidney function failure et al . 3．Severely allergic biologic product . 4．Pregnancy breastfeeding . 5．Current treatment another clinical trail . 6．Any condition investigator judge patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Severe aplastic anemia</keyword>
	<keyword>immunosuppressive therapy</keyword>
	<keyword>cord blood transfusion</keyword>
</DOC>